Targets › IL2RG
14 programs from 14 companies in 48 trials: 23 Phase 1, 21 Phase 2, 4 Phase 3; Oncology, Immunology, Metabolic and endocrine; next expected readout Nov 2026.
Common subunit for the receptors for a variety of interleukins. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. (UniProt, P31785)
Open in Phaseline: the race on IL2RG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ImmunityBio | Nogapendekin Alfa Inbakicept (N803) Interleukin-15 receptor agonist | IL2RG, IL2RB, IL15RA | Phase 3 | NSCLC Stage IV; Long COVID; Platinum-resistant Ovarian Cancer; Relapsed B-Cell Non Hodgkin Lymphoma … | Mar 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Daclizumab (CD25) Interleukin-2 receptor inhibitor | IL2RA, IL2RG, IL2RB | Phase 3 | Graft Versus Host Disease | May 2028 |
| CellTrans | Basiliximab Interleukin-2 receptor inhibitor | IL2RA, IL2RG, IL2RB | Phase 3 | Type 1 Diabetes Mellitus; Renal Transplant Rejection; Recurrent Hodgkin Lymphoma; Acute Lymphoblastic Leukemia | – |
| Dana-Farber Cancer Institute | Aldesleukin Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Chronic Graft-versus-host Disease; Acute Myeloid Leukemia; Platinum-resistant Ovarian Cancer; Chronic Graft Versus Host Disease | Nov 2026 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Aldesleukin Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Stage IV Colorectal Cancer; Head Neck Tumors; Mesothelioma, Malignant | Dec 2026 |
| M.D. Anderson Cancer Center | Aldesleukin Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Melanoma; Metastatic Melanoma; Metastatic Malignant Neoplasm in the Lung | Oct 2027 |
| Assistance Publique - Hôpitaux de Paris | Aldesleukin (ILT-101) Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Type 1 Diabetes | Nov 2027 |
| AgonOx | DP CD8 TIL KD Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 1 | HNSCC | Dec 2026 |
| Sanofi | Pegenzileukin IL-2R beta/gamma agonist | IL2RG, IL2RB | Phase 1 | Plasma Cell Myeloma Refractory | Sep 2027 |
| David Williams | autologous CD34+ cell transduced with G2SCID vector Lentiviral gene transfer delivering functional IL2RG (common gamma chain) gene to correct | IL2RG | Phase 1 | Severe Combined Immunodeficiency, X Linked | Jan 2028 |
| National Cancer Institute (NCI) | Recombinant Human Interleukin-15 (rhIL-15) Interleukin-15 receptor agonist | IL2RG, IL2RB, IL15RA | Phase 1 | Neuroblastoma | Jun 2028 |
| H. Lee Moffitt Cancer Center and Research Institute | Interleukin-2 (IL-2) Cytokine to support TIL expansion and activation | IL2RA, IL2RB, IL2RG | Phase 1 | Lymphocytes | Sep 2029 |
| Alexander B Olawaiye, MD | Denileukin Diftitox (E7777) Elongation factor 2 inhibitor; Interleukin-2 receptor binding agent | EEF2, IL2RA, IL2RG, IL2RB | Phase 1 | Epithelial Ovarian Cancer | May 2030 |
| National Institute of Allergy and Infectious Diseases (NIAID) | VSV-G pseudotyped CL20-4i-EF1alpha-hgammac-OPT lentiviral vector Lentiviral vector-mediated gene transfer delivering functional IL2RG (common gamma chain) | IL2RG | Phase 1 | X-linked Severe Combined Immunodeficiency (XSCID) | Dec 2032 |
Acute Myeloid Leukemia (3) Platinum-resistant Ovarian Cancer (2) Long COVID (2) Melanoma (1) Metastatic Melanoma (1) Metastatic Malignant Neoplasm in the Lung (1) Plasma Cell Myeloma Refractory (1) Chronic Graft-versus-host Disease (1) Chronic Graft Versus Host Disease (1) Epithelial Ovarian Cancer (1) NSCLC Stage IV (1) Relapsed B-Cell Non Hodgkin Lymphoma (1)
mixed (8), protein or peptide (4), small molecule (1), other (1)
M.D. Anderson Cancer Center (1) Sanofi (1) Dana-Farber Cancer Institute (1) Alexander B Olawaiye, MD (1) ImmunityBio (1) Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) National Cancer Institute (NCI) (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Assistance Publique - Hôpitaux de Paris (1) David Williams (1) H. Lee Moffitt Cancer Center and Research Institute (1) AgonOx (1) CellTrans (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.